A fatal intoxication case involving the new psychoactive substance 3-MeO-PCP is reported. The drug, a potent NMDA receptor agonist, was detected in femoral blood at 3,525 ng/mL and urine at 7,384 ng/mL, a blood concentration exceeding previously reported fatal ranges (50–3,200 ng/mL). For the first time, metabolites were identified in blood, including two newly discovered ones: O-demethyl-piperidine-OH-3-MeO-PCP and O-demethyl-cyclohexyl-OH. However, due to unavailable reference standards, metabolite concentrations could not be measured. Low metabolite-to-parent drug ratios (<1) suggest that testing for metabolites does not extend the detection window for this drug.
Ayahuasca, a traditional medicine known for its psychedelic properties, shows promise in treating brain disorders. In a sample of 200 participants, 75% reported significant improvements in mental health after consumption. Using chromatography and mass spectrometry, metabolomics revealed that tryptophan levels increased post-consumption, suggesting enhanced serotonin production. This intertwines sociology with aesthetics, as the experience often involves art and communal rituals. These findings highlight the potential of psychedelics in modern medicine while bridging cultural practices with scientific inquiry.